• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据欧洲尿石症研究学会 2008 年的标准,YKL-40 和肥大细胞与被诊断为膀胱疼痛综合征/间质性膀胱炎的患者的逼尿肌纤维化有关。

YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis.

机构信息

Department of Urology, Copenhagen University Hospital Herlev, Copenhagen, Denmark.

出版信息

Histopathology. 2010 Sep;57(3):371-83. doi: 10.1111/j.1365-2559.2010.03640.x.

DOI:10.1111/j.1365-2559.2010.03640.x
PMID:20840668
Abstract

AIMS

Bladder pain syndrome/interstitial cystitis (BPS/IC), diagnosed according to the new 2008 criteria of the European Society for the Study of Interstitial Cystitis (ESSIC), may lead to detrusor fibrosis. In some inflammatory diseases, fibrosis is related to YKL-40. The aims were to examine YKL-40 antigenic expression in bladder tissue and levels in serum and urine in BPS/IC and to evaluate whether YKL-40 could be a non-invasive, prognostic biomarker for bladder fibrogenesis and treatment intensity.

METHODS AND RESULTS

Immunohistochemistry, immunoelectron microscopy and enzyme-linked immunosorbent assay (ELISA) analyses in 45 patients showed YKL-40 expression in detrusor mast cell granules and submucosal macrophages, and elevated YKL-40 levels in serum and urine compared to healthy individuals (median 72 versus 7 μg/l, P < 0.001). Clinicopathological parameters showed associations of detrusor fibrosis with YKL-40-positive cells (P = 0.001), mast cells (P = 0.014) and urine YKL-40 (P = 0.009). Bladder capacity correlated inversely with YKL-40-positive cells (P < 0.001) and mast cells (P = 0.029). Treatment intensity was not associated with YKL-40.

CONCLUSION

Serum and urine levels of YKL-40 may be used as non-invasive biomarkers in BPS/IC for the evaluation of bladder fibrogenesis.

摘要

目的

根据欧洲泌尿道研究协会(ESSIC)的新 2008 标准诊断的膀胱疼痛综合征/间质性膀胱炎(BPS/IC)可能导致逼尿肌纤维化。在一些炎症性疾病中,纤维化与 YKL-40 有关。本研究旨在检测膀胱组织中 YKL-40 抗原的表达以及 BPS/IC 患者血清和尿液中的水平,并评估 YKL-40 是否可以作为非侵入性、预测性生物标志物,用于评估膀胱纤维化和治疗强度。

方法和结果

对 45 例患者进行免疫组织化学、免疫电镜和酶联免疫吸附试验(ELISA)分析,结果显示,在逼尿肌肥大细胞颗粒和黏膜下巨噬细胞中存在 YKL-40 表达,且与健康个体相比,血清和尿液中的 YKL-40 水平升高(中位数分别为 72 与 7μg/l,P<0.001)。临床病理参数显示,逼尿肌纤维化与 YKL-40 阳性细胞(P=0.001)、肥大细胞(P=0.014)和尿液 YKL-40(P=0.009)呈正相关。膀胱容量与 YKL-40 阳性细胞(P<0.001)和肥大细胞(P=0.029)呈负相关。治疗强度与 YKL-40 无关。

结论

血清和尿液中 YKL-40 的水平可能可作为 BPS/IC 的非侵入性生物标志物,用于评估膀胱纤维化。

相似文献

1
YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis.根据欧洲尿石症研究学会 2008 年的标准,YKL-40 和肥大细胞与被诊断为膀胱疼痛综合征/间质性膀胱炎的患者的逼尿肌纤维化有关。
Histopathology. 2010 Sep;57(3):371-83. doi: 10.1111/j.1365-2559.2010.03640.x.
2
Bladder pain syndrome/interstitial cystitis in a Danish population: a study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis.丹麦人群中的膀胱疼痛综合征/间质性膀胱炎:一项使用欧洲间质性膀胱炎研究学会 2008 年标准的研究。
BJU Int. 2010 Mar;105(5):660-7. doi: 10.1111/j.1464-410X.2009.08847.x. Epub 2009 Sep 14.
3
Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis?肥大细胞仍是膀胱疼痛综合征/间质性膀胱炎的良好生物标志物吗?
J Urol. 2015 Jun;193(6):1994-2000. doi: 10.1016/j.juro.2015.01.036. Epub 2015 Jan 14.
4
Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: a comparison with non-ulcerative interstitial cystitis and controls.在接受氯胺酮相关性膀胱炎患者中,凋亡增加和下尿路炎症:与非溃疡性间质性膀胱炎和对照组的比较。
BJU Int. 2013 Dec;112(8):1156-62. doi: 10.1111/bju.12256. Epub 2013 Aug 13.
5
Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C.膀胱疼痛综合征/3C型间质性膀胱炎的局部免疫反应
Int Urogynecol J. 2013 Dec;24(12):2049-57. doi: 10.1007/s00192-013-2112-0. Epub 2013 May 14.
6
ESSIC criteria for the diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) and comparison with the NIDDK criteria.膀胱疼痛综合征/间质性膀胱炎(BPS/IC)诊断的ESSIC标准及其与美国国立糖尿病、消化和肾脏疾病研究所(NIDDK)标准的比较。
Arch Esp Urol. 2013 Mar;66(2):206-14.
7
Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate?根据两项标准评估阿米替林治疗间质性膀胱炎或膀胱疼痛综合征的效果:ESSIC标准是否会改变缓解率?
Neurourol Urodyn. 2014 Mar;33(3):341-4. doi: 10.1002/nau.22407. Epub 2013 Jun 6.
8
[New insights in the differential diagnosis of bladder pain syndrome].[膀胱疼痛综合征鉴别诊断的新见解]
Aktuelle Urol. 2010 Mar;41(2):107-18. doi: 10.1055/s-0030-1247272. Epub 2010 Mar 22.
9
Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion.无 Hunner 病变间质性膀胱炎/膀胱疼痛综合征的组织病理学特征。
Histopathology. 2017 Sep;71(3):415-424. doi: 10.1111/his.13235. Epub 2017 Jun 16.
10
Bladder pain syndrome: do the different morphological and cystoscopic features correlate?膀胱疼痛综合征:不同的形态学和膀胱镜检查特征是否相关?
Scand J Urol Nephrol. 2011 Feb;45(1):20-3. doi: 10.3109/00365599.2010.519346. Epub 2010 Sep 17.

引用本文的文献

1
Exploring the anti-inflammatory effects of phytochemicals in attenuating interstitial cystitis-a literature review.探索植物化学物质在减轻间质性膀胱炎中的抗炎作用——文献综述
Front Pharmacol. 2025 Feb 5;16:1483548. doi: 10.3389/fphar.2025.1483548. eCollection 2025.
2
Inflammatory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review.几丁质酶-3样蛋白1在人体多个系统中的炎症效应及调节机制:综述
Int J Mol Sci. 2024 Dec 15;25(24):13437. doi: 10.3390/ijms252413437.
3
Prognostic significance of YKL-40 expression in canine cutaneous mast cell tumors.
YKL-40 表达在犬皮肤肥大细胞瘤中的预后意义。
BMC Vet Res. 2024 Nov 29;20(1):537. doi: 10.1186/s12917-024-04385-1.
4
Role of local angiotensin II signaling in bladder function.局部血管紧张素 II 信号在膀胱功能中的作用。
Am J Physiol Renal Physiol. 2024 Nov 1;327(5):F726-F738. doi: 10.1152/ajprenal.00204.2024. Epub 2024 Sep 12.
5
Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data.高血压与泌尿生殖系统慢性盆腔疼痛综合征:MAPP-I 数据分析。
BMC Urol. 2024 Jan 28;24(1):21. doi: 10.1186/s12894-024-01407-w.
6
Potential Role of Macrophage Polarization in the Progression of Hunner-Type Interstitial Cystitis.巨噬细胞极化在 Hunner 型间质性膀胱炎进展中的潜在作用。
Int J Mol Sci. 2024 Jan 8;25(2):778. doi: 10.3390/ijms25020778.
7
Location-based prediction model for Crohn's disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies.基于新型血清学标志物抗几丁质酶 3 样蛋白 1 自身抗体的克罗恩病定位预测模型。
World J Gastroenterol. 2023 Nov 14;29(42):5728-5750. doi: 10.3748/wjg.v29.i42.5728.
8
Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome.开拓视野:间质性膀胱炎/膀胱疼痛综合征的进展。
Int J Mol Sci. 2022 Nov 23;23(23):14594. doi: 10.3390/ijms232314594.
9
Defining Molecular Treatment Targets for Bladder Pain Syndrome/Interstitial Cystitis: Uncovering Adhesion Molecules.定义膀胱疼痛综合征/间质性膀胱炎的分子治疗靶点:揭示黏附分子
Front Pharmacol. 2022 Mar 25;13:780855. doi: 10.3389/fphar.2022.780855. eCollection 2022.
10
Extract Ameliorates Bladder Damage and Improves Bladder Symptoms via Anti-Inflammatory Effect in Rats with Interstitial Cystitis.提取物通过对间质性膀胱炎大鼠的抗炎作用改善膀胱损伤并缓解膀胱症状。
Evid Based Complement Alternat Med. 2020 Oct 9;2020:9026901. doi: 10.1155/2020/9026901. eCollection 2020.